Cargando…
Central serous chorioretinopathy following the BNT162b2 mRNA vaccine
BACKGROUND AND PURPOSE: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has accelerated vaccine development. The BNT162b2 messenger RNA (mRNA) vaccine is being administered worldwide. The purpose of this case series is to report a possible association between the BNT162b2 mRNA vaccine a...
Autores principales: | Hanhart, J., Roditi, E., Wasser, L.M., Barhoum, W., Zadok, D., Brosh, K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Masson SAS.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099405/ https://www.ncbi.nlm.nih.gov/pubmed/35577701 http://dx.doi.org/10.1016/j.jfo.2022.01.006 |
Ejemplares similares
-
Central serous chorioretinopathy following oral quetiapine
por: Durmaz Engin, Ceren, et al.
Publicado: (2023) -
The Genetic Background of Central Serous Chorioretinopathy: A Review on Central Serous Chorioretinopathy Genes
por: Giannopoulos, Konstantinos, et al.
Publicado: (2021) -
Oropharyngeal shedding of herpesviruses before and after BNT162b2 mRNA vaccination against COVID-19
por: Brosh-Nissimov, Tal, et al.
Publicado: (2021) -
Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination
por: Gouda, Wesam, et al.
Publicado: (2022) -
Traumatic central serous chorioretinopathy
por: Ramchandani, Suresh, et al.
Publicado: (2015)